In 2015, Capital International had purchased a 11 percent stake in Mankind Pharma from ChrysCapital for $200 million. In April 2018, a ChrysCapital-led consortium, which included GIC and CPPPIB, made a stunning comeback and bought a 10 percent stake again for around $350 million. Earlier in the year, Mankind Pharma had acquired the formulations brands of listed player Panacea Biotec in India and Nepal for Rs 1,872 crore to explore new therapeutic areas.
हिन्दी 
English